Milestone Pharmaceuticals Inc.

MIST

CA59935V1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
1.5 ^USD	-1.96%		-12.28%	-10.18%

05-29	Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia	MT
05-29	Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST?	CI

Milestone Pharmaceuticals Inc. Announces the Retirement of Francis Plat as Chief Scientific Officer, Effective December 31, 2022

December 06, 2022 at 04:37 pm

Milestone Pharmaceuticals Inc. announced that Mr. Francis Plat's intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.

Latest news about Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia	05-29	MT
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST?	05-29	CI
Certain Pre-Funded Warrants of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.	05-28	CI
Certain Options of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.	05-28	CI
Certain Common Shares of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.	05-28	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	04-08	CI
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	03-28	MT
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	03-28	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating	03-05	MT
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA	02-26	DJ
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt	02-26	CI
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating	12-27	MT
Milestone Pharmaceuticals Says FDA Issued Refusal-to-File Letter for New Drug Application for Etripamil; Shares Fall Pre-Bell	12-26	MT
Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA	12-26	DJ
Top Premarket Decliners	12-26	MT
Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter	12-26	DJ
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT	12-26	CI
Transcript : Milestone Pharmaceuticals Inc. - Shareholder/Analyst Call	11-13
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Alta Advisers Sends a Letter to Milestone Pharmaceuticals	11-09	CI
Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil	23-10-24	CI
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating	23-08-11	MT

Chart Milestone Pharmaceuticals Inc.

Duration

Period

More charts

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.5 USD

Average target price

10.25 USD

Spread / Average Target

+583.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MILESTONE PHARMACEUTICALS INC.	-10.18%	99.23M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs